{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:40:27Z","timestamp":1786372827038,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2018,4]]},"abstract":"\n Background and objectives<\/jats:title>\n In patients with CKD, elevated plasma parathyroid hormone (PTH) levels are associated with greater cardiovascular morbidity and mortality. However, the reference method for PTH measurement is disputed. It has been argued that measurement of nonoxidized PTH better reflects biologically active PTH than measurements with conventional assays.<\/jats:p>\n <\/jats:sec>\n \n Design, setting, participants, & measurements<\/jats:title>\n \n PTH and nonoxidized PTH levels were measured at study baseline in 535 patients with CKD with an eGFR range between 89 and 15 ml\/min per 1.73 m\n 2<\/jats:sup>\n . Patients were followed over 5.1 years for the occurrence of acute heart failure, atherosclerotic events, CKD progression (doubling of serum creatinine or initiation of RRT), or all-cause death.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Atherosclerotic events, acute heart failure, CKD progression, and deaths from any cause occurred in 116, 58, 73, and 85 patients, respectively. In Kaplan\u2013Meier analyses, patients at the highest PTH and nonoxidized-PTH tertile (79\u2013543 and 12\u2013172 pg\/ml, respectively) showed a higher rate of atherosclerotic events, acute heart failure, CKD progression, and death from any cause. After adjustment for eGFR and albuminuria, nonoxidized PTH was no longer associated with atherosclerotic events (hazard ratio third versus first tertile, 1.04 [95% confidence intervals, 0.62\u20131.75]), acute heart failure (hazard ratio third versus first tertile, 1.24 [95% confidence intervals, 0.59\u20132.62]), CKD progression (hazard ratio third versus first tertile, 0.93 [95% confidence intervals, 0.46\u20131.90]), and death from any cause (hazard ratio third versus first tertile, 1.23 [95% confidence intervals, 0.66\u20132.31]), and PTH lost its association with atherosclerotic events (hazard ratio third versus first tertile, 0.80 [95% confidence intervals, 0.46\u20131.38]) and CKD progression (hazard ratio third versus first tertile, 0.99 [95% confidence intervals, 0.46\u20132.10]), although it remained associated with acute heart failure (hazard ratio third versus first tertile, 2.76 [95% confidence intervals, 1.11\u20136.89]) and all-cause death (hazard ratio third versus first tertile, 2.35 [95% confidence intervals, 1.13\u20134.89]). After further adjustment for cardiovascular and kidney risk factors, PTH remained associated with all-cause death (hazard ratio third versus first tertile, 2.79 [95% confidence intervals, 1.32\u20135.89]), but with no other end point.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In a cohort of patients with CKD, PTH was associated with all-cause mortality; there was no association of nonoxidized PTH with any of the clinical outcomes examined.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.06620617","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T20:20:15Z","timestamp":1520281215000},"page":"569-576","source":"Crossref","is-referenced-by-count":34,"title":["Association of Nonoxidized Parathyroid Hormone with Cardiovascular and Kidney Disease Outcomes in Chronic Kidney Disease"],"prefix":"10.2215","volume":"13","author":[{"given":"Sarah","family":"Seiler-Mussler","sequence":"first","affiliation":[{"name":"Department of Internal Medicine IV\u2013Nephrology and Hypertension, Saarland University Medical Centre, Homburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"Limbach","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV\u2013Nephrology and Hypertension, Saarland University Medical Centre, Homburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insa E.","family":"Emrich","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV\u2013Nephrology and Hypertension, Saarland University Medical Centre, Homburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Pickering","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Otago, Christchurch, New Zealand;"},{"name":"Department of Emergency, Christchurch Hospital, Christchurch, New Zealand; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz J.","family":"Roth","sequence":"additional","affiliation":[{"name":"Medizinisches Versorgungszentrum Dr. Limbach und Kollegen, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Fliser","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV\u2013Nephrology and Hypertension, Saarland University Medical Centre, Homburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar H.","family":"Heine","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV\u2013Nephrology and Hypertension, Saarland University Medical Centre, Homburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,3,5]]},"reference":[{"key":"B1-20230813","first-page":"239","article-title":"Cardiovascular disease and mortality in ESRD.","volume":"11","author":"Foley","year":"1998","journal-title":"J Nephrol"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1681\/ASN.V92267","article-title":"Mode of dialysis therapy and mortality in end-stage renal disease.","volume":"9","author":"Foley","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/jama.2009.1488","article-title":"Cardiovascular and noncardiovascular mortality among patients starting dialysis.","volume":"302","author":"de Jager","year":"2009","journal-title":"JAMA"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney Int"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: What\u2019s changed and why it matters.","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease.","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options.","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1053\/j.ajkd.2008.05.020","article-title":"Disordered mineral metabolism in hemodialysis patients: An analysis of cumulative effects in the Hemodialysis (HEMO) Study.","volume":"52","author":"Wald","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS).","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"221","DOI":"10.11613\/BM.2010.027","article-title":"Evolution and current state of assays for measuring parathyroid hormone.","volume":"20","author":"Skugor","year":"2010","journal-title":"Biochem Med (Zagreb)"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1046\/j.1523-1755.2002.00600.x","article-title":"The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia.","volume":"62","author":"Himmelfarb","year":"2002","journal-title":"Kidney Int"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ndt\/gfg074","article-title":"Oxidative stress in end-stage renal disease: An emerging threat to patient outcome.","volume":"18","author":"Locatelli","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1016\/S0021-9258(19)39415-3","article-title":"Effect of methionine oxidation and deletion of amino-terminal residues on the conformation of parathyroid hormone. Circular dichroism studies.","volume":"265","author":"Zull","year":"1990","journal-title":"J Biol Chem"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/jbmr.5650030316","article-title":"Effects of oxidation of human parathyroid hormone on its biological activity in continuously infused, thyroparathyroidectomized rats.","volume":"3","author":"Horiuchi","year":"1988","journal-title":"J Bone Miner Res"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1210\/jc.2013-2139","article-title":"Nonoxidized, biologically active parathyroid hormone determines mortality in hemodialysis patients.","volume":"98","author":"Tepel","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"e40242","DOI":"10.1371\/journal.pone.0040242","article-title":"Measuring parathyroid hormone (PTH) in patients with oxidative stress--do we need a fourth generation parathyroid hormone assay?","volume":"7","author":"Hocher","year":"2012","journal-title":"PLoS One"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000455289","article-title":"Why current PTH assays mislead clinical decision making in patients with secondary hyperparathyroidism.","volume":"136","author":"Hocher","year":"2017","journal-title":"Nephron"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2215\/CJN.07870713","article-title":"Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4.","volume":"9","author":"Seiler","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/ki.2012.288","article-title":"Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease.","volume":"83","author":"Seiler","year":"2013","journal-title":"Kidney Int"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction.","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/STROKEAHA.110.592642","article-title":"Stroke incidence and survival in Ludwigshafen am Rhein, Germany: The Ludwigshafen Stroke Study (LuSSt).","volume":"41","author":"Palm","year":"2010","journal-title":"Stroke"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jacc.2011.03.069","article-title":"Vitamin D, parathyroid hormone, and cardiovascular events among older adults.","volume":"58","author":"Kestenbaum","year":"2011","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201804000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:37:44Z","timestamp":1786369064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201804000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,5]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.06620617","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,5]]}}}